Progress of selinexor for treatment of hematologic malignancies
10.3760/cma.j.cn115356-20230812-00163
- VernacularTitle:塞利尼索治疗血液肿瘤的研究进展
- Author:
Gongai WANG
1
;
Yunliang HAO
Author Information
1. 济宁市第一人民医院血液内科，济宁 272000
- Keywords:
Multiple myeloma;
Lymphoma;
Leukemia;
Selinexor;
Hematologic neoplasms
- From:
Journal of Leukemia & Lymphoma
2024;33(12):762-765
- CountryChina
- Language:Chinese
-
Abstract:
The treatment outcome of hematologic malignancies is generally poor. The continuing emergence of a variety of targeted therapies still cannot meet clinical requirements. Selinexor is a first-generation selective inhibitor of nuclear export, which is widely used in the preclinical and clinical studies of malignancies. It plays an important role in relapsed/refractory hematologic malignancies and has been approved by the U.S. Food and Drug Administration for treatment of relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma. Many clinical studies have shown that selinexor is effective in other hematological malignancies. This article reviews the application progress of selinexor in treatment of multiple myeloma, leukemia and lymphoma.
